Beneath the market noise and enforcement positioning, a structural formation is becoming unmistakable. The federal rescheduling pathway for psilocybin — assessed at 82% probability of not occurring before 2028 — is not frozen by scientific uncertainty alone. It is frozen by procedural architecture: DEA concurrence requirements, mandatory HHS review cycles, public comment periods, and final rule publication create an 18-to-24-month minimum lag from any formal initiation, and no formal initiation has begun. This means that every clinical milestone — every COMPASS Phase 3 readout, every positive trial publication — feeds a scientific record that cannot yet be converted into federal access. The highest trajectory genuinely available from this constraint is not a federal breakthrough in 2026 but a deepening of the state-level infrastructure that will ultimately make federal rescheduling less consequential than it currently appears. Three or more additional states introducing therapeutic access or decriminalization legislation before year-end is a conservative forecast, not an optimistic one. Oregon and Colorado did not just open doors — they built a distributed architecture that is now self-replicating below the federal threshold. That is where the real formation is happening.
For the veterans who remain the dominant political frame for every piece of psychedelic reform legislation moving through Congress — assessed at 74% probability of remaining so through 2026 regardless of whether any bill passes — this structural moment is both hopeful and agonizing in equal measure. They are watching treatment approaches that have shown measurable clinical signal for treatment-resistant PTSD move through institutional channels calibrated for a different era's risk tolerance. The FDA's caution on MDMA is a legitimate regulatory function and a genuine cost simultaneously — that tension is real and not resolvable by choosing one side. What is genuinely possible for these individuals is not a policy miracle in 2026 but the slow, durable construction of legal state pathways that create real access within the next 24 to 36 months, undergirded by a bipartisan veteran framing durable enough to survive DEA pressure and political headwinds. That is the highest timeline the current moment actually supports — not fantasy, not capitulation, but the grinding, specific, state-by-state opening of a door that cannot now be fully closed.
OOTW doesn't sell products. It delivers transmissions — a daily reminder that the intelligence which created us is still creating, still calling us forward.
What is being called in cannot be called back.
82%
Psilocybin won't be rescheduled federally before 2028
The federal government won't move psilocybin to a less restricted category before January 2028, even if Congress pushes hard or new research comes out. The actual rescheduling process takes 18–24 months minimum and involves the DEA (Drug Enforcement Administration), HHS (Department of Health and Human Services), a public comment period, and final paperwork — and nobody has even formally started yet.
→ Bureaucratic timelines, not politics, block federal psilocybin rescheduling until 2028 at earliest.
Resolves: 2028-01-01 · USA
REGULATION
the precise call ▾
Federal psilocybin rescheduling will not occur before 2028-01-01 regardless of 2026 legislative or clinical developments.. Administrative rescheduling requires sequential DEA concurrence, HHS review, public comment period, and final rule publication — a process that takes a minimum of 18-24 months from formal initiation. No formal initiation has begun as of June 2026. The procedural math makes pre-2028 rescheduling stru
77%
Three more states legalize psilocybin therapy or decriminalize before 2026 ends
At least three more U.S. states will introduce bills to either let therapists use psilocybin legally or decriminalize small amounts before December 31, 2026. Oregon and Colorado already did this, and other states like California and Washington have activist groups pushing hard. When the federal government can't agree on something, states usually try it first — that's what happened with cannabis, and it's happening with psychedelics now.
→ State-level psilocybin legalization is accelerating; three more states will formally propose access legislation by end of 2026.
Resolves: 2026-12-31 · USA
LEGISLATION
the precise call ▾
At least three additional U.S. states will introduce psilocybin decriminalization or therapeutic access legislation before 2026-12-31.. Oregon and Colorado have created a replicable legislative template. Federal gridlock historically accelerates state-level experimentation — this pattern is well-documented in cannabis, where a handful of early movers triggered a cascade. Three states is a deliberately conservative floor given that s
74%
Compass stock drops back to $12.80–$13.40 within one week
A psychedelic company's stock (CMPS) went up 11% in one day with no actual news. That's a classic sign that retail traders jumped in fast. When that happens, the stock almost always comes back down within a week or two because professional investors don't chase moves like that without real company developments — new FDA (Food and Drug Administration) approval, a partnership, something concrete.
→ An 11% stock gain on no news usually evaporates within days — this one will likely drop back to $12.80–$13.40.
Resolves: 2026-06-10 · USA
MARKET
the precise call ▾
CMPS will retrace to between $12.80 and $13.40 within 7 trading days absent a formal FDA or partnership announcement.. An 11.4% single-session gain on no press release is a textbook retail momentum trade. Institutional capital does not chase moves of this magnitude in small-cap biotech without a catalyst on the wire. Mean reversion is the base case: the move lacks a durable fundamental anchor, and momentum traders t
73%
DEA will publicly prosecute unlicensed retreat operators before September 2026
The DEA (Drug Enforcement Administration) will announce at least two enforcement actions — arrests, indictments, or raids — against illegal psilocybin retreat operators running in the U.S. before September 1, 2026. When federal drug laws face challenges, enforcement agencies fight back by cracking down visibly. Recent deaths at unregulated retreats give the DEA a legitimate public-safety reason to act.
→ The DEA will publicly prosecute at least two unlicensed psilocybin retreat operators before September 2026 to reassert control.
Resolves: 2026-09-01 · USA
ENFORCEMENT
the precise call ▾
DEA will initiate at least two publicly announced enforcement actions against unregulated psychedelic retreat operators in the U.S. before 2026-09-01.. When controlled-substance scheduling faces legislative challenge, enforcement agencies typically assert operational precedent to preserve jurisdictional authority. Recent high-profile incidents — including a frog-poison retreat death — provide DEA with defensible public-safety justification. Two act
72%
U.S. lawmakers will frame psychedelic reform around veterans
When Congress introduces bills about psychedelics in 2026, most of them will emphasize helping military veterans with PTSD (post-traumatic stress disorder) and other service-related trauma. This framing works because it sidesteps culture-war arguments — nobody wants to deny veterans new medical options. Advocacy groups like MAPS (Multidisciplinary Association for Psychedelic Studies) have deliberately chosen this angle, and it attracts both Democratic and Republican support.
→ Veterans' mental health will be the primary political frame for U.S. psychedelic reform bills in 2026.
Resolves: 2026-12-31 · USA
POLITICS
the precise call ▾
Veterans will remain the dominant political framing for U.S. psychedelic reform legislation introduced or advanced in 2026, appearing in the primary title or stated purpose of the majority of federal bills.. Veterans framing neutralizes culture-war opposition, attracts bipartisan co-sponsors, and has been the explicit strategy of MAPS and allied advocacy groups for several legislative cycles. This prediction is falsifiable: resolution requires reviewing the stated purpose sections of federal psychedelic